Global Myasthenia Gravis Disease Market Research Report 2019 By Diagnosis (Imaging, Blood Tests, Electrodiagnostic, Edrophonium Test), Treatment (Medication, Surgery, HSCT), End-User (Hospitals, Clinics, Academic Research Institutes) – Global Forecast Till 2023
This condition occurs due to the impairment of communication between muscles and nerve cells. This impairment causes difficulties in the contraction and relaxation of muscles which are crucial for carrying out daily activities, resulting in muscle weakness.
Factors such as increasing cases of neuromuscular disorders, growing awareness regarding the treatment line, and increasing number of clinical facilities across the region are driving the market growth. However, the high cost of treatment and ignorance of signs and symptoms are constraining the growth of the market.
The global myasthenia gravis disease market is expected to Rise with a strong CAGR 0f 7.5% over the forecast period from 2017 to 2023.
Avail FREE Sample of this Research at: https://www.marketresearchfuture.com/sample_request/5843
Major Key Players Competitive Analysis:
Leading players in the global myasthenia gravis disease market include Fresenius Kabi, GSK plc, AbbVie Inc., Biogen Inc., Bristol-Myers Squibb Co., F. Hoffman-La Roche Ltd., Cipla, RPG Life Sciences, Teva Pharmaceutical Industries Ltd., Apotex Corporation, Novartis, Piramal Healthcare, Sun Pharmaceuticals Industries Ltd., and Valeant.
a new case report from a man suffering from both multiple sclerosis and myasthenia gravis showed that the two diseases may share common autoimmune responses. In August 2019, a research team from Chongqing Medical University and SUNY Upstate Medical University found that gut microbes and metabolic changes could provide an accurate biomarker for myasthenia gravis disease. Such efforts are likely to remain crucial for the global myasthenia gravis disease market over the forecast period.
Market Segmentation:
The global myasthenia gravis disease market has been segmented on the basis of diagnosis, treatment, and end-user.
On the basis of diagnosis, the global myasthenia gravis disease market can be segmented into imaging, blood tests, electrodiagnostic, edrophonium tests, pulmonary function tests, and others. The imaging segment is classified into X-ray, computed tomography (CT), magnetic resonance imaging (MRI), and others.
On the basis of treatment, the global myasthenia gravis disease market can be segmented into medication, surgery, autologous hematopoietic stem cell transplantation (HSCT), plasmapheresis and intravenous immunoglobulin, and others. By medication, the market is divided into acetylcholinesterase inhibitors, immunosuppressants, steroids, and others. The acetylcholinesterase inhibitors segment is further classified into atropine, neostigmine, pyridostigmine, and others. Immunosuppressant drugs are further divided into azathioprine, mycophenolate mofetil, tacrolimus, and rituximab. The steroids segment is further divided into prednisone and others. Surgery is divided into thymectomy and others.
On the basis of end user, the global myasthenia gravis disease market is segmented into hospitals, clinics, academic research institutes, and others.
Chapter 4. Market Dynamics
- 1 Drivers
- 2 Restraints
- 3 Opportunities
- 4 Challenges
- 5 Macroeconomic Indicators
- 6 Technology Trends & Assessment
Browse Complete 100 Pages Research Report along with Detailed TOC Enabled at: https://www.marketresearchfuture.com/reports/myasthenia-gravis-disease-market-5843
Regional Analysis:
The global myasthenia gravis disease market is expected to be dominated by North America over the forecast period, with the Americas segment holding the dominant share in the market. The Americas market for myasthenia gravis disease is mainly driven by the growing awareness about the disease, as neurological diseases have been studied in detail in the region and awareness about this kind of disease is significantly high in the region. The growing demand for effective medications for neuromuscular diseases such as myasthenia gravis is likely to drive the drug development scenario in the Americas region over the forecast period, leading to steady growth of the myasthenia gravis disease market.
Europe holds the second largest share in the global myasthenia gravis disease market and is likely to remain a leading contender in the global market over the forecast period due to the growing awareness about neuromuscular conditions. Myasthenia gravis holds a significant position in the Europe market, as the disease can cause a significant burden on national healthcare systems
Asia Pacific is likely to be a major regional with increasing desire to eliminate the disease from urban populations in growing economies such as China, India, Japan, and South Korea. Increasing healthcare expenditure in the region is likely to be a major driver for the myasthenia gravis disease market over the forecast period. Rising awareness about neuromuscular diseases is likely to be a key driver for the myasthenia gravis disease market in Asia Pacific over the forecast period.
Ask for an Amazing Discount Or Any Customizations Feel FREE to Contact https://www.marketresearchfuture.com/enquiry/5843
The Middle East and Africa is likely to retain a low share in the global myasthenia gravis disease market over the forecast period due to the lack of awareness about the disease in the region and the low disposable income of consumers in the region.
About Market Research Future: MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact:
Market Research Future
+1 646 845 9312
Your information will never be shared with any third party.